Dapagliflozin, a sodium-glucose co-transporter 2 inhibitor, acutely reduces energy expenditure in BAT via neural signals in mice

PLoS ONE

Volumn 11, Issue 3, 2016, Pages

  Chiba, Yumiko ^a   Yamada, Tetsuya ^a   Tsukita, Sohei ^a   Takahashi, Kei ^a   Munakata, Yuichiro ^a   Shirai, Yuta ^a   Kodama, Shinjiro ^a   Asai, Yoichiro ^a   Sugisawa, Takashi ^a   Uno, Kenji ^a   Sawada, Shojiro ^a   Imai, Junta ^a   Nakamura, Kazuhiro ^b   Katagiri, Hideki ^a,c  

^a TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c JAPAN AGENCY FOR MEDICAL RESEARCH AND DEVELOPMENT   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

DAPAGLIFLOZIN; NORADRENALIN; PROTEIN C FOS; UNCOUPLING PROTEIN 1; 2-(3-(4-ETHOXYBENZYL)-4-CHLOROPHENYL)-6-HYDROXYMETHYLTETRAHYDRO-2H-PYRAN-3,4,5-TRIOL; BENZHYDRYL DERIVATIVE; GLUCOSIDE; GLYCOGEN; ION CHANNEL; MITOCHONDRIAL PROTEIN; SLC5A2 PROTEIN, MOUSE; SODIUM GLUCOSE COTRANSPORTER 2; UCP1 PROTEIN, MOUSE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BROWN ADIPOSE TISSUE; CONTROLLED STUDY; DRUG DETERMINATION; DRUG EFFECT; ENERGY EXPENDITURE; GLYCOGEN ANALYSIS; MALE; MOUSE; NERVE CELL NETWORK; NONHUMAN; NUCLEUS RAPHE PALLIDUS; OXYGEN CONSUMPTION; PROTEIN EXPRESSION; SYMPATHETIC NERVE; THERMOGENESIS; UPREGULATION; ANIMAL; ANTAGONISTS AND INHIBITORS; BIOSYNTHESIS; CARBOHYDRATE METABOLISM; DRUG EFFECTS; ENERGY METABOLISM; GENE EXPRESSION REGULATION; LIVER; METABOLISM; MIDBRAIN RAPHE NUCLEUS; SYNAPTIC TRANSMISSION; VAGUS NERVE;

ADIPOSE TISSUE, BROWN; ANIMALS; BENZHYDRYL COMPOUNDS; CARBOHYDRATE METABOLISM; ENERGY METABOLISM; GENE EXPRESSION REGULATION; GLUCOSIDES; GLYCOGEN; ION CHANNELS; LIVER; MALE; MICE; MIDBRAIN RAPHE NUCLEI; MITOCHONDRIAL PROTEINS; PROTO-ONCOGENE PROTEINS C-FOS; SODIUM-GLUCOSE TRANSPORTER 2; SYNAPTIC TRANSMISSION; THERMOGENESIS; UNCOUPLING PROTEIN 1; VAGUS NERVE;

EID: 84962482429     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0150756     Document Type: Article

References (24)

1. Vallon V (2015) The mechanisms and therapeutic potential of SGLT2 inhibitors in diabetes mellitus. Annu Rev Med 66:255-270. doi: 10.1146/annurev-med-051013-110046 PMID: 25341005
2. Ferrannini E, Solini A (2012) SGLT2 inhibition in diabetes mellitus: rationale and clinical prospects. Nat Rev Endocrinol 8:495-502. doi: 10.1038/nrendo.2011.243 PMID: 22310849
3. Bailey CJ (2011) Renal glucose reabsorption inhibitors to treat diabetes. Trends Pharmacol Sci 32:63-71. doi: 10.1016/j.tips.2010.11.011 PMID: 21211857
4. List JF, Woo V, Morales E, Tang W, Fiedorek FT (2009) Sodium-glucose cotransport inhibition with dapagliflozin in type 2 diabetes. Diabetes Care 32:650-657. doi: 10.2337/dc08-1863 PMID: 19114612
5. Vickers SP, Cheetham SC, Headland KR, Dickinson K, Grempler R, et al. (2014) Combination of the sodium-glucose cotransporter-2 inhibitor empagliflozin with orlistat or sibutramine further improves the body-weight reduction and glucose homeostasis of obese rats fed a cafeteria diet. Diabetes Metab Syndr Obes 7:265-275. doi: 10.2147/DMSO. S58786 PMID: 25061325
6. Devenny JJ, Godonis HE, Harvey SJ, Rooney S, Cullen MJ, et al. (2012) Weight loss induced by chronic dapagliflozin treatment is attenuated by compensatory hyperphagia in diet-induced obese (DIO) rats. Obesity (Silver Spring) 20:1645-1652.
7. Nagata T, Fukuzawa T, Takeda M, Fukazawa M, Mori T, et al. (2013) Tofogliflozin, a novel sodium-glucose co-transporter 2 inhibitor, improves renal and pancreatic function in db/db mice. Br J Pharmacol 170:519-531. doi: 10.1111/bph.12269 PMID: 23751087
8. Ferrannini G, Hach T, Crowe S, Sanghvi A, Hall KD, et al. (2015) Energy Balance After Sodium-Glucose Cotransporter 2 Inhibition. Diabetes Care 38:1730-1735. doi: 10.2337/dc15-0355 PMID: 26180105
9. Takahashi K, Yamada T, Tsukita S, Kaneko K, Shirai Y, et al. (2013) Chronic mild stress alters circadian expressions of molecular clock genes in the liver. Am J Physiol Endocrinol Metab 304:E301-309. doi: 10.1152/ajpendo.00388.2012 PMID: 23211520
10. Tsukita S, Yamada T, Uno K, Takahashi K, Kaneko K, et al. (2012) Hepatic glucokinase modulates obesity predisposition by regulating BAT thermogenesis via neural signals. Cell Metab 16:825-832. doi: 10.1016/j.cmet.2012.11.006 PMID: 23217261
11. Uno K, Katagiri H, Yamada T, Ishigaki Y, Ogihara T, et al. (2006) Neuronal pathway from the liver modulates energy expenditure and systemic insulin sensitivity. Science 312:1656-1659. PMID: 16778057
12. Desautels M, Dulos RA (1988) Effects of repeated cycles of fasting-refeeding on brown adipose tissue composition in mice. Am J Physiol 255:E120-128. PMID: 3407768
13. Morrison SF, Nakamura K, Madden CJ (2008) Central control of thermogenesis in mammals. Exp Physiol 93:773-797. doi: 10.1113/expphysiol.2007.041848 PMID: 18469069
14. Young JB, Saville E, Rothwell NJ, Stock MJ, Landsberg L (1982) Effect of diet and cold exposure on norepinephrine turnover in brown adipose tissue of the rat. J Clin Invest 69:1061-1071. PMID: 7068845
15. Nakamura K, Matsumura K, Kaneko T, Kobayashi S, Katoh H, et al. (2002) The rostral raphe pallidus nucleus mediates pyrogenic transmission from the preoptic area. J Neurosci 22:4600-4610. PMID: 12040067
16. Izumida Y, Yahagi N, Takeuchi Y, Nishi M, Shikama A, et al. (2013) Glycogen shortage during fasting triggers liver-brain-adipose neurocircuitry to facilitate fat utilization. Nat Commun 4:2316. doi: 10.1038/ncomms3316 PMID: 23939267
17. Uno K, Yamada T, Ishigaki Y, Imai J, Hasegawa Y, et al. (2015) A hepatic amino acid/mTOR/S6Kdependent signalling pathway modulates systemic lipid metabolism via neuronal signals. Nat Commun 6:7940. doi: 10.1038/ncomms8940 PMID: 26268630
18. Yokono M, Takasu T, Hayashizaki Y, Mitsuoka K, Kihara R, et al. (2014) SGLT2 selective inhibitor ipragliflozin reduces body fat mass by increasing fatty acid oxidation in high-fat diet-induced obese rats. Eur J Pharmacol 727:66-74. doi: 10.1016/j.ejphar.2014.01.040 PMID: 24486393
19. Van Marken Lichtenbelt WD, Schrauwen P (2011) Implications of nonshivering thermogenesis for energy balance regulation in humans. Am J Physiol Regul Integr Comp Physiol 301:R285-296. doi: 10.1152/ajpregu.00652.2010 PMID: 21490370
20. Shibata H, Bukowiecki LJ (1987) Regulatory alterations of daily energy expenditure induced by fasting or overfeeding in unrestrained rats. J Appl Physiol (1985) 63:465-470.
21. Berthoud HR (2004) Anatomy and function of sensory hepatic nerves. Anat Rec A Discov Mol Cell Evol Biol 280:827-835. PMID: 15382018
22. Tahara A, Kurosaki E, Yokono M, Yamajuku D, Kihara R, et al. (2012) Pharmacological profile of ipragliflozin (ASP1941), a novel selective SGLT2 inhibitor, in vitro and in vivo. Naunyn Schmiedebergs Arch Pharmacol 385:423-436. doi: 10.1007/s00210-011-0713-z PMID: 22139434
23. Chen LH, Leung PS (2013) Inhibition of the sodium glucose co-transporter-2: its beneficial action and potential combination therapy for type 2 diabetes mellitus. Diabetes Obes Metab 15:392-402. doi: 10. 1111/dom.12064 PMID: 23331516
24. Niijima A (1988) The effect of endogenous sugar acids on the afferent discharge rate of the hepatic branch of the vagus nerve in the rat. Physiol Behav 44:661-664. PMID: 2853388